## **Dimitrios H Roukos**

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5368054/dimitrios-h-roukos-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 120
 6,353
 57
 75

 papers
 citations
 h-index
 g-index

 236
 6,975
 4.6
 6.58

 ext. papers
 ext. citations
 avg, IF
 L-index

#	Paper	IF	Citations
120	Proof-of-Concept Pilot Study on Comprehensive Spatiotemporal Intra-Patient Heterogeneity for Colorectal Cancer With Liver Metastasis <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 855463	5.3	1
119	Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 80, 101894	14.4	22
118	Precision oncology in patients with nonmetastatic disease: emerging reality or illusion. <i>Future Oncology</i> , <b>2019</b> , 15, 1805-1810	3.6	
117	Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy. <i>Drug Discovery Today</i> , <b>2019</b> , 24, 1281-1294	8.8	12
116	Bulk and Single-Cell Next-Generation Sequencing: Individualizing Treatment for Colorectal Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	10
115	Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. <i>Medicinal Research Reviews</i> , <b>2019</b> , 39, 1205-1227	14.4	15
114	Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. <i>Drug Discovery Today</i> , <b>2018</b> , 23, 1848-1872	8.8	7
113	Precision in personalized prediction-based medicine. <i>Personalized Medicine</i> , <b>2018</b> , 15, 467-470	2.2	
112	Breakthrough cancer genome analysis in time and space: novel oncotargets and early drug development. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 1303-1310	2.6	
111	Early solid tumor diagnosis through next-generation sequencing of cell-free DNA. <i>Biomarkers in Medicine</i> , <b>2018</b> , 12, 1197-1201	2.3	1
110	Identification of novel genes by whole-exome sequencing can improve gastric cancer precision oncology. <i>Future Oncology</i> , <b>2017</b> , 13, 883-892	3.6	5
109	Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. <i>Drug Discovery Today</i> , <b>2017</b> , 22, 1148-1164	8.8	17
108	From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	8
107	Primary liver cancer genome sequencing: translational implications and challenges. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2017</b> , 11, 875-883	4.2	2
106	Intratumor heterogeneity: predicting and preventing therapeutic resistance. <i>Biomarkers in Medicine</i> , <b>2016</b> , 10, 681-4	2.3	1
105	Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies. <i>Drug Discovery Today</i> , <b>2016</b> , 21, 663-73	8.8	12
104	Continuous intraoperative neuromonitoring in thyroid surgery: Safety analysis of 400 consecutive electrode probe placements with standardized procedures. <i>Head and Neck</i> , <b>2016</b> , 38 Suppl 1, E1568-74	4.2	26

103	The role of heat shock proteins in cancer. Cancer Letters, 2015, 360, 114-8	9.9	199
102	Neoadjuvant chemotherapy in locally advanced gastric cancer: what to avoid. Preliminary analysis of a consecutive series of patients. <i>Tumori</i> , <b>2015</b> , 101, 511-6	1.7	
101	Targeted Therapy and Novel Agents for the Treatment of Gastric Cancer: A View Toward the Future <b>2015</b> , 317-330		
100	Laparoscopic gastrectomy for gastric cancer: current evidences. <i>International Journal of Surgery</i> , <b>2014</b> , 12, 1369-73	7.5	16
99	Application of microRNAs in diabetes mellitus. <i>Journal of Endocrinology</i> , <b>2014</b> , 222, R1-R10	4.7	91
98	Intraoperative neuromonitoring of the external branch of the superior laryngeal nerve during thyroidectomy: the need for evidence-based data and perioperative technical/technological standardization. <i>Scientific World Journal, The</i> , <b>2014</b> , 2014, 692365	2.2	7
97	Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. <i>OncoTargets and Therapy</i> , <b>2014</b> , 7, 491-500	4.4	17
96	Dynamic sequencing of circulating tumor DNA: novel noninvasive cancer biomarker. <i>Biomarkers in Medicine</i> , <b>2014</b> , 8, 629-32	2.3	4
95	BMI and lymph node ratio may predict clinical outcomes of gastric cancer. <i>Future Oncology</i> , <b>2014</b> , 10, 249-55	3.6	10
94	Genome network medicine: innovation to overcome huge challenges in cancer therapy. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , <b>2014</b> , 6, 201-8	6.6	6
93	Novel next-generation sequencing and networks-based therapeutic targets: realistic and more effective drug design and discovery. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 11-22	3.3	12
92	The Evolution of High-Throughput Sequencing Technologies: From Sanger to Single-Molecule Sequencing <b>2013</b> , 1-30		
91	Integrative deep-sequencing analysis of cancer samples: discoveries and clinical challenges. <i>Pharmacogenomics Journal</i> , <b>2013</b> , 13, 205-8	3.5	3
90	Integrating NGS and third-generation sequencing technologies into clinical genomic medicine <b>2013</b> , 6-	18	
89	Research and clinical applications of cancer genome sequencing. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2013</b> , 25, 3-10	2.4	10
88	Next-Generation Sequencing & Molecular Diagnostics 2013,		1
87	Translating complex genomic discoveries into molecular diagnostic tests 2013, 2-5		
86	Next-Generation Sequencing in Cancer Epigenomics and Potential Clinical Applications <b>2013</b> , 31-53		1

85	Translating cancer genomes sequencing revolution into surgical oncology practice. <i>Journal of Surgical Research</i> , <b>2012</b> , 173, 365-9	2.5	6
84	Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. <i>Modern Pathology</i> , <b>2012</b> , 25, 1055-68	9.8	31
83	Fruit and vegetable intake and the risk of gastric adenocarcinoma: a reanalysis of the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study after a longer follow-up. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 2910-9	7.5	93
82	Chromatin: a key player in complex gene regulation and future cancer therapeutics. <i>Epigenomics</i> , <b>2011</b> , 3, 395-9	4.4	20
81	Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. <i>Pharmacogenomics Journal</i> , <b>2011</b> , 11, 81-92	3.5	58
80	Standards, advances and challenges in laparoscopic total mesorectal excision. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2011</b> , 25, 333-5	5.2	1
79	Omitting axilla lymphadenectomy even by positive sentinel lymph node: a change in breast cancer treatment practice. <i>Womenps Health</i> , <b>2011</b> , 7, 417-8	3	3
78	Targeting the individual cancer patient <b>2011</b> , 8-28		1
77	Personalized genomic medicine: is a cancer care revolution achievable? <b>2011</b> , 2-6		
76	Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e279-80; author reply e282-3	2.2	32
75	Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 1187-95	3.5	16
74	Individual genomes and personalized medicine: life diversity and complexity. <i>Personalized Medicine</i> , <b>2010</b> , 7, 347-350	2.2	81
73	Comparative-effectiveness research to standardize retrieved nodes for quality control in colorectal cancer. <i>Annals of Surgery</i> , <b>2010</b> , 252, 202-3; author reply 203	7.8	1
72	Laparoscopic and robotic rectal cancer resection: expectations for improving oncological outcomes. <i>Annals of Surgery</i> , <b>2010</b> , 251, 185-6; author reply 186	7.8	9
71	Standardizing lymphadenectomy for rectal cancer. <i>Annals of Surgery</i> , <b>2010</b> , 252, 569; author reply 569.	- <b>70</b> <sub>7</sub> .8	
70	Limitations of isolated tumor cells in gastric cancer: heterogeneity requests systems biology approaches towards personalized medicine. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 343-4; author reply 345	3.1	2
69	Caution in adding bevacizumab in the adjuvant treatment of breast cancer. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 653-4; author reply 655-6	3.1	
68	HER-2-negative breast cancer limitations and next-generation sequencing technology promises. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 1720	3.1	3

## (2009-2010)

67	Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. <i>Expert Review of Molecular Diagnostics</i> , <b>2010</b> , 10, 33-48	3.8	82
66	Quality control in colorectal cancer care: how many lymph nodes should be harvested?. <i>World Journal of Surgery</i> , <b>2010</b> , 34, 864-5; author reply 866-7	3.3	1
65	Ten years after human genome sequencing: is personalized breast screening and prevention reality?. World Journal of Surgery, <b>2010</b> , 34, 2786-7; author reply 2788-9	3.3	
64	Thresholds and combined quality control in the multimodal treatment of colorectal cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2010</b> , 24, 1789-90	5.2	
63	New technology-based innovation changes surgical practice and research direction in solid cancers. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2010</b> , 24, 2916-7	5.2	
62	Hope from Japan for esophagogastric cancers: esophagectomy and endoscopic submucosal dissection for gastric tube cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2010</b> , 24, 292	4-5	
61	Totally intracorporeal laparoscopic gastrectomy for gastric cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2010</b> , 24, 3247-8; author reply 3249-50	5.2	3
60	Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1337-8; author reply 1338-9	2.2	74
59	Esophagus and Gastric Cancer: How Surgeon® Experience and Personal Genomics May Improve Locoregional Control and Survival. <i>World Journal of Surgery</i> , <b>2009</b> , 33, 161-2	3.3	
58	Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the "Gordian Knot"?. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 774-5; author reply 776-7	3.1	85
57	Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 772-3	3.1	97
56	Circulating cancer cells: could they be used in the clinic as recurrence markers for gastric and colorectal cancer?. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 778-9; author reply 780-2	3.1	
55	Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 1771-82	3.1	80
54	Magnetic resonance imaging and potential impact on extent of surgery in breast cancer. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 2953-4; author reply 2955	3.1	
53	Challenges in personalizing decisions on whole, partial or no breast irradiation and extent of surgery for early breast cancer. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 2656-7; author reply 2658	3.1	1
52	Totally laparoscopic gastrectomy: a reality for USA and Europe?. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 2665-6; author reply 2667	3.1	5
51	Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. <i>Annals of Surgery</i> , <b>2009</b> , 250, 349-50; author reply 350	7.8	58
50	Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. <i>Annals of Surgery</i> , <b>2009</b> , 250, 650-1; author reply 651	7.8	49

49	Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. <i>Annals of Surgery</i> , <b>2009</b> , 249, 1067-8	7.8	67
48	Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true?. <i>Annals of Surgery</i> , <b>2009</b> , 249, 695-6; author reply 697	7.8	50
47	Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. <i>Expert Review of Molecular Diagnostics</i> , <b>2008</b> , 8, 587-97	3.8	75
46	Does lymphadenectomy improve survival of patients with solid tumors?. <i>Annals of Surgical Oncology</i> , <b>2008</b> , 15, 385; author reply 388-9	3.1	1
45	Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. <i>Expert Review of Molecular Diagnostics</i> , <b>2008</b> , 8, 29-39	3.8	75
44	Increased risk of local recurrence after breast-conserving therapy in young patients. <i>Radiotherapy and Oncology</i> , <b>2008</b> , 86, 286-7; author reply 287-8	5.3	1
43	Linking contralateral breast cancer with genetics. Radiotherapy and Oncology, 2008, 86, 139-41	5.3	65
42	Genomics and challenges toward personalized breast cancer local control. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4360-1; author reply 4361-2	2.2	75
41	Contralateral prophylactic mastectomy: mind the genetics. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1909-10; author reply 1910	2.2	8
40	Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. <i>Annals of Surgery</i> , <b>2008</b> , 247, 714-5; author reply 715-6	7.8	67
39	Outcomes of breast cancer patients with and without BRCA1/2 mutations. <i>International Journal of Cancer</i> , <b>2008</b> , 122, 1918-9	7.5	
38	EGFR as a Prognostic Marker for Gastric Cancer. <i>World Journal of Surgery</i> , <b>2008</b> , 32, 1225-6; author reply 1227-9	3.3	7
37	Robotic surgery for rectal cancer: may it improve also survival?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2008</b> , 22, 1405-6	5.2	63
36	Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2008</b> , 22, 1402-4	5.2	43
35	The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. <i>Annals of Surgical Oncology</i> , <b>2008</b> , 15, 21-33	3.1	101
34	More controversy than ever - challenges and promises towards personalized treatment of gastric cancer. <i>Annals of Surgical Oncology</i> , <b>2008</b> , 15, 956-60	3.1	80
33	Targeting VEGF, EGFR, and other interacting pathways for gastric cancer-promises and reality. <i>Annals of Surgical Oncology</i> , <b>2008</b> , 15, 2981-2; author reply 2983-5	3.1	7
32	HER2 and trastuzumab: impact of a new standard agent on local control and surgery for breast cancer. <i>Annals of Surgical Oncology</i> , <b>2008</b> , 15, 3614-5; author reply 3616	3.1	2

## (2005-2008)

31	HER2 and response to paclitaxel in node-positive breast cancer. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 197; author reply 198	59.2	30
30	Breast-cancer stromal cells with TP53 mutations. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 1636; author reply 1636	59.2	52
29	Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 308-12	4.6	104
28	Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. <i>Nature Clinical Practice Oncology</i> , <b>2007</b> , 4, 578-90		107
27	Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). <i>Scandinavian Journal of Gastroenterology</i> , <b>2007</b> , 42, 618-27	2.4	41
26	Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 1555-6; author reply 1556	59.2	29
25	Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). <i>International Journal of Cancer</i> , <b>2006</b> , 118, 2559-66	7.5	258
24	Can VEGF-D and VEGFR-3 be used as biomarkers for therapeutic decisions in patients with gastric cancer?. <i>Nature Clinical Practice Oncology</i> , <b>2006</b> , 3, 418-9		3
23	Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). <i>Journal of the National Cancer Institute</i> , <b>2006</b> , 98, 345-54	9.7	247
22	Does a new model improve decisions about mismatch-repair genetic testing and Lynch syndrome identification?. <i>Nature Clinical Practice Oncology</i> , <b>2006</b> , 3, 656-7		3
21	Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2006</b> , 6, 931-9	3.5	69
20	Is an aromatase inhibitor more effective than tamoxifen in neoadjuvant endocrine therapy for breast cancer?. <i>Nature Clinical Practice Oncology</i> , <b>2006</b> , 3, 82-3		1
19	Surgery in the era of gene expression profiling-based prediction and individualized, neoadjuvant breast cancer therapy: the beginning of the end?. <i>Annals of Surgical Oncology</i> , <b>2006</b> , 13, 433-5	3.1	4
18	Does neoadjuvant versus adjuvant systemic treatment improve outcomes in breast cancer?. <i>Nature Clinical Practice Oncology</i> , <b>2005</b> , 2, 342-3		1
17	It Is Still Not the Time to Change Surgical Strategy for Gastric Cancer. <i>Annals of Surgical Oncology</i> , <b>2005</b> , 12, 194-196	3.1	1
16	Factors increasing local recurrence in breast-conserving surgery. <i>Expert Review of Anticancer Therapy</i> , <b>2005</b> , 5, 737-45	3.5	72
15	Perspectives in the treatment of gastric cancer. <i>Nature Clinical Practice Oncology</i> , <b>2005</b> , 2, 98-107		146
14	Impact of spleen preservation in patients with gastric cancer. <i>Anticancer Research</i> , <b>2005</b> , 25, 3023-30	2.3	22

13	Early-stage gastric cancer: a highly treatable disease. <i>Annals of Surgical Oncology</i> , <b>2004</b> , 11, 127-9	3.1	77
12	The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. <i>Cancer Treatment Reviews</i> , <b>2004</b> , 30, 205-11	14.4	129
11	Breast and gastric cancer: comparing what we learn. <i>Annals of Surgical Oncology</i> , <b>2003</b> , 10, 92-4	3.1	4
10	Fruits and vegetables: do they protect from gastric cancer?. <i>Gastroenterology</i> , <b>2003</b> , 124, 2006-7; author reply 2007	13.3	5
9	Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. <i>Annals of Surgical Oncology</i> , <b>2000</b> , 7, 719-26	3.1	77
8	Adjuvant chemotherapy in gastric cancer. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 3061-2	2.2	1
7	Relevant prognostic factors in gastric cancer. <i>Annals of Surgery</i> , <b>2000</b> , 232, 719-20	7.8	4
6	Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. <i>Annals of Surgical Oncology</i> , <b>1999</b> , 6, 46-56	3.1	106
5	Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. <i>Surgery</i> , <b>1998</b> , 123, 573-8	3.6	126
4	Effectiveness of extended lymphadenectomy in noncurative gastrectomy. <i>American Journal of Surgery</i> , <b>1996</b> , 172, 303	2.7	2
3	Effectiveness of extended lymphadenectomy in early gastric cancer. Surgery, 1996, 119, 238-9	3.6	3
2	A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. <i>Annals of Surgery</i> , <b>1996</b> , 224, 108-9	7.8	
1	A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach. An analysis of early results and long-term survival. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>1990</b> , 116, 307-13	4.9	66